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Poly-prolinea b s t r a c t
In this study, we performed a mutational analysis to determine whether the mechanism by which
HIV-2 Vpx confers the capacity for infectivity and viral replication in macrophages is solely depen-
dent on its ability to degrade the host antiviral factor SAMHD1. Contrary to expectations, we demon-
strated that P109 in the C-terminal poly-proline motif of HIV-2 Vpx has two unique roles: to facilitate
the speciﬁc degradation of SAMHD1 in macrophages, and to facilitate multimerization of Vpx,
therefore preventing SAMHD1 degradation in the presence of high levels of Vpx.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Human immunodeﬁciency virus (HIV), which is the causative
agent of AIDS, is classiﬁed into two types, HIV-1 and HIV-2 [1].
Each type has a unique set of accessory proteins: HIV-1 carries
Vif, Vpr, Vpu and Nef, while HIV-2 carries Vif, Vpx, Vpr and Nef.
After the studies of Vif [2–4], some accessory proteins have been
shown to act as adaptors of the E3 ubiquitin ligase complex to
antagonize host antiviral factors; thus, providing advantages in
viral replication [5].
Vpx, an HIV-2-speciﬁc accessory protein, has been shown to be
essential for virus replication in macrophages in vitro [6–11] and
important in activated T lymphocytes [6,9,11,12]. Furthermore,
Vpx is critical for SIV infection in monkeys in vivo [13–15].
Studies have indicated that signiﬁcant amounts of Vpx packaged
into virions [16–19] perform a function within the target cells.
Vpx is critical for reverse transcription of the viral RNAgenome in macrophages [10,20] and dendritic cells of
macrophage lineage [21]. This process is induced by the
formation of a Cul4-DDB1-DCAF1 E3 ligase complex and the
proteasome-dependent degradation of a restriction factor [22–
24], identiﬁed as SAMHD1 in 2011 [25,26]. Research indicated that
SAMHD1 reduces deoxynucleotide triphosphate (dNTP) pools
[27,28], which are components of viral genomic cDNA, and sup-
presses its reverse transcription in macrophages [29,30].
However, subsequent studies have indicated that the dNTPase
activity of SAMHD1 is not absolutely required for its antiviral activ-
ity [31–33]. It was also reported that SAMHD1 has 30 ? 50 exonu-
clease activity against ssDNAs and ssRNAs [34]. Recently, direct
degradation of viral RNA mediated by the RNase activity of
SAMHD1 was shown to be the dominant function of this protein,
although the contribution of its dNTPase activity cannot be com-
pletely dismissed [35]. In addition to the function of Vpx in the
degradation of SAMHD1, we hypothesized that Vpx possesses a
SAMHD1-degradation independent function that enhances HIV-2
growth in T lymphocytes [36]. However, the latter function has
not been demonstrated to inﬂuence viral growth in macrophages.
We have previously analyzed the replication of HIV-2 mutants
carrying 19 point mutations in scattered regions of the vpx gene
in macrophages [10]. Here, we investigated the ability of these
mutants to degrade SAMHD1 in the human kidney cell line 293T,
and compared their effects on viral infectivity in macrophages. A
1506 H.I. Ciftci et al. / FEBS Letters 589 (2015) 1505–1514relatively good correlation was identiﬁed between these two char-
acteristics among this panel of mutants. We next analyzed the
properties of the mutants that were not related to this correlation,
and unexpectedly found that the residue P109 within the
C-terminal poly-proline motif (PPM) of Vpx plays a unique role
in the regulation of SAMHD1 degradation.
2. Materials and methods
2.1. Plasmids
See Supplementary material.
2.2. Cell culture and transfection
The human kidney cell line 293T [40] was maintained in
Dulbecco’s modiﬁed Eagle’s medium supplemented with 10%
heat-inactivated fetal bovine serum (FBS), and the human mono-
cytic cell line THP-1 [41] was cultured in RPMI-1640 supplemented
with 10% heat-inactivated FBS and 55 lM 2-mercaptoethanol.
Monocyte-derived macrophages were prepared using GM-CSF as
previously described [42]. Transfection of 293T cells with various
plasmids was routinely performed by the calcium-phosphate
co-precipitation method [43]. Exceptionally, transfection of
full-length HIV-2 molecular clone pGL-AN or its mutant into
293T cells to observe cellular Vpx protein was performed using
Lipofectamine 3000 (Life Technologies, Carlsbad, CA, USA) to
increase transfection efﬁciency. Transfected cells were incubated
for 2 or 3 days post-transfection before use in experiments.
2.3. Immunoblot analysis
Cells were lysed in PBS-Laemmli sample buffer (1:1), and
immunoblot analysis was performed as described previously
[44]. As an antibody, anti-FLAG M2 (Sigma–Aldrich, St Louis, MO,
USA) (1:1000), anti-b-actin clone AC-15 (Sigma–Aldrich)
(1:1000), anti-myc-antibody (Life Technologies, Carlsbad, CA,
USA) (1:1000), monoclonal anti-HA.11 clone 16B12 (Covance,
Princeton, NJ, USA) (1:1000), anti-monomeric Kusabira–Green
N-terminal fragment mAb (MBL, Nagoya, Japan) (1:1000),
anti-monomeric Kusabira–Green C-terminal fragment mAb (MBL)
(1:1000), HIV-2 Vpx monoclonal antibody 6D2.6 (NIH AIDS
Research and References Reagent Program) [45] (1:1000), HIV-2
Rod polyclonal antibody (NIH AIDS Research and References
Reagent Program) [46] (1:200), antiserum to SIV-p27 (NIBSC
Centralized Facility for AIDS reagent) (1:1000), or anti-SAMHD1
antibody (Abcam, Cambridge, UK) (1:500) was used.
Immunoreactivity was detected by chemiluminescence using
ImmunoStar Zeta (for p27 detection), or ImmunoStar LD (for detec-
tion of the other proteins) (Wako Pure Chemical Industries, Osaka,
Japan).
2.4. Bimolecular ﬂuorescence complementation assay
The assay was performed using Kusabira–Green system [47].
For microscopic observation, all-in-one ﬂuorescence microscope
Biorevo BZ-9000 (Keyence, Osaka, Japan) was used (excitation,
470/40 nm; absorption, 535/50 nm).
2.5. Virion preparation and quantitative PCR analysis
Virions were prepared using Viro-Adembeads (Ademtech,
Pessac, France) or ultracentrifugation using sucrose as described
previously [48]. Quantitative PCR analysis was performed accord-
ing to the same methods used in our previous report [10].3. Results
3.1. Expression proﬁles of Vpx mutants
We previously performed mutational analysis using a series of
mutants of the HIV-2 infectious clone pGL-AN [38] carrying 19
point mutations in scattered regions of Vpx (Fig. 1(a)) [10]. To
examine the ability of the mutants to degrade SAMHD1, the muta-
tions were introduced into pEF-Fvpx. This vector expresses high
levels of Vpx carrying a FLAG-tag at its N-terminus [37], which
has been reported to have no inﬂuence of the function of Vpx
[49]. The pEF-Fvpx vector or its mutants were transfected into
293T cells, and expression from the mutant vectors was examined
by western immunoblot analysis. As shown in Fig. 1(b), all the vec-
tors expressed mutant Vpx, although the expression levels varied.
Furthermore, two bands were observed for many of the mutant
proteins. The upper band was considered to be attributed to phos-
phorylated Vpx; therefore, Phos-tag electrophoresis [50] followed
by western immunoblot analysis of the mutants was performed.
As shown in Fig. 1(c), the upper bands showed retarded migration
in the electrophoresis. These proteins were treated then with
lambda protein phosphatase, and analyzed by Phos-tag elec-
trophoresis. In the presence of phosphatase, the upper bands were
apparently lost, while the position of the lower bands did not
change (Fig. 1(d)). These results clearly conﬁrmed that the upper
bands could be attributed to phosphorylated Vpx, while the lower
bands were attributed to unphosphorylated Vpx.
3.2. The ability of Vpx mutants to degrade SAMHD1
To examine the ability of the mutants to degrade SAMHD1, 293T
cells were co-transfected with 1.9 lg of pEF-Fvpx [37], and 1.4 lg of
the myc-tagged human SAMHD1 expression vector (pcDNA
hSAMHD1) or empty vector. Cells were lysed, and the steady-state
expression levels of SAMHD1 were examined by western immuno-
blot analysis. Surprisingly, the expression levels of SAMHD1 with
and without Vpx were almost identical. We speculated that the
excessive amounts of Vpx protein expressed from 1.9 lg of
pEF-Fvpx would prevent the degradation of SAMHD1. To test this
hypothesis, the amount of pEF-Fvpx was gradually reduced from
1.9 lg to 0.0075 lg, and transfected into 293T cells with 1.4 lg of
pcDNA hSAMHD1. The levels of SAMHD1 were then analyzed by
western immunoblotting (Fig. 2(a)). SAMHD1 level was efﬁciently
reduced in cells transfected with 0.03 lg or 0.06 lg pEF-Fvpx.
These results showed that large amounts of Vpx prevent the degra-
dation of SAMHD1; therefore, identiﬁcation of the appropriate
amounts of Vpx expression vector was important for our analysis.
In subsequent experiments, we used 0.06 lg of pEF-Fvpx or its
mutants. These vectors and pcDNA hSAMHD1 were co-transfected
into 293T cells, and the steady-state expression levels were exam-
ined (Fig. 2(b)). The mutants P4L, N33S, E43G, C87A, H94A, P103A
and P109A were found to degrade SAMHD1 with similar efﬁciency
to that mediated by WT Vpx. Conversely, the other twelve mutants
did not demonstrate the capacity to degrade SAMHD1 under these
experimental conditions. To exclude the possibility that the amount
of each mutant vector (0.06 lg) was insufﬁcient to allow SAMHD1
degradation, we repeated these experiments using greater amounts
(0.0075–1.9 lg) of mutant vectors. As shown in Fig. 2(c), the
mutants P10L, E15G, E20G, W24L, W56L and Q76A did not degrade
SAMHD1 under these experimental conditions. The other mutants
reduced SAMHD1 levels with high or medium efﬁciency at speciﬁc
concentrations of the vector.
These results, together with those of our previous mutational
analysis [10] and the recently resolved crystal structure of the





Fig. 1. Expression of Vpx mutants. (a) Positions of the introduced mutations [10,56]. Structure of Vpx [GL-AN clone [38] carrying 112 aa (GenBank accession No. M30895),
Vpx sequence of GL-AN was originated from that of GH-123 [57]] having three major helices [58] is shown. Positions of the mutations are shown with arrows. For example,
P4L is a mutant carrying L instead of the 4th P. (b) Immunoblot analysis of proteins in 293T cells transfected with expression vector for FLAG-tagged Vpx [37] or its mutants
(3.3 lg). Mock, pEF1/myc-HisA. (c) Immunoblot analysis after electrophoresis using 15% SuperSep Phos-tag of the proteins used in (b). (d) Effect of phosphatase on expression
of Vpx and its mutants. The proteins used in (b) dissolved in PBS-Laemmli’s sample buffer (1:1) were diluted with PBS supplemented with 0.1% BSA (5), and
immunoprecipitated with anti-FLAG M2 afﬁnity gel (Sigma–Aldrich). The gel was washed once with PBS containing 0.1% BSA, and the precipitated proteins were treated with
lambda protein phosphatase, and analyzed by immunoblotting with ANTI-FLAG M2 after Phos-tag electrophoresis.
H.I. Ciftci et al. / FEBS Letters 589 (2015) 1505–1514 1507Notably, while this structure shows interaction of the amino acids
S63 and R70 with SAMHD1 and DCAF1, respectively, S63A and
R70A have moderate ability to degrade SAMHD1, suggesting that
these interactions are not critical for the formation of the E3
ligase complex. While a relationship between Vpx protein phos-
phorylation and virus growth has not yet been deﬁned, the
expression level of the protein observed in this experimental sys-
tem appeared to be related to the virus replication in macro-
phages. The ﬁve mutants showing low Vpx expression showed
none or few of the properties of the WT properties with regard
to viral growth. Apart from these mutants, the ability to reduce
SAMHD1 level tended to be consistent with growth in
macrophages. Exceptions were P10L, E30G, C87A and P109A.
Among these mutants, C87A and P109A degraded SAMHD1 with
an efﬁciency similar to that mediated by the WT (Fig. 2(b)), but
exhibited average importance for virus replication in macro-
phages; therefore, we focused on these as candidates for mutants
lacking the SAMHD1-degradation independent function of Vpx.
3.3. The ability of the P109A mutant to degrade SAMHD1 at its high
expression level and form Vpx–Vpx interaction
To investigate the effects of the expression levels of the C87A
and P109A mutants on the ability to degrade SAMHD1 compared
with that mediated by the WT Vpx, we repeated our previousexperiments in which the amount of the vectors expressing the
mutants was reduced from 1.9 lg to 0.0075 lg, and transfected
into 293T cells with 1.4 lg of pcDNA hSAMHD1. As shown in
Fig. 3(a), the C87A and P109A mutants reduced SAMHD1 levels
effectively at both higher and lower concentrations than those
observed for effective degradation by WT Vpx, indicating the
enhanced ability of C87A and P109A to degrade SAMHD1.
Surprisingly, the P109A mutant also degraded SAMHD1 efﬁciently
at high concentrations of the expression vector, leading us to spec-
ulate that this property is speciﬁc to the P109A mutant. To inves-
tigate this issue, we selected six mutants which degraded
SAMHD1 following transfection of 0.06 lg of the vector
(Fig. 2(b)) and expressed sufﬁcient levels of protein (Fig. 1(b)).
We investigated the ability of the mutants to degrade SAMHD1
when transfected at high levels (1.9 lg). As shown in Fig. 3(b),
while P109A degraded SAMHD1, the other ﬁve mutants did not
degrade the protein, showing the ability to degrade SAMHD1 at
high levels was a characteristic speciﬁc to P109A. Notably, the
Vpx mutant P109A itself underwent degradation during the pro-
cess of its degradation of SAMHD1 (Fig. 3(b)). The P109 residue is
located in the C-terminal poly-proline motif (PPM) having seven
consecutive prolines. We next examined whether this character
of P109A is seen in the other mutants of PPM. As shown in
Fig. 3(c and d), P106A shows the ability to degrade SAMHD1 both




Fig. 2. Degradation of SAMHD1 in the presence of Vpx or its various point mutants. (a) Immunoblot analysis of proteins in 293T cells co-transfected with the expression
vector for myc-tagged SAMHD1 (pcDNA hSAMHD1) (1.4 lg), and various amounts (1.9–0.0075 lg) of expression vector for FLAG-tagged Vpx (pEF-Fvpx) [37] [total amounts
of vectors were adjusted to 3.3 lg using an empty vector pEF1/myc-HisA]. (b) Western immunoblot analysis of proteins in 293T cells co-transfected with pcDNA hSAMHD1
(3.24 lg), and pEF-Fvpx or its mutants (0.06 lg). (c) The same analysis as (a) using various mutants of pEF-Fvpx instead of pEF-Fvpx. Blots were developed as long as possible
to increase the sensitivity of Vpx detection. For some mutants, the expression level of SAMHD1 was lower than that observed in cells co-transfected with 0.06 lg of the Vpx
mutant vectors, as shown in (b). This phenomenon could be due to discrepancies in the amounts of the SAMHD1 expression vector used in these two sets of experiments. (d)
Phenotypes of various Vpx point mutants with respect to SAMHD1 degradation and the other characteristics shown in this and another study. Growth kinetics in human
macrophages were previously reported by us [10]. Expression level and phosphorylation are according to the results in Fig. 1. The mutants showing degradation of SAMHD1
similar to the WT in (b) are classiﬁed as ‘‘WT or similar to WT properties’’. For the mutants which degrade SAMHD1 in (c), higher amounts of vector are required for the
degradation than that of WT, or the degree of degradation is less than that mediated by the WT; these mutants are categorized as ‘‘moderate properties’’. The interactions
with SAMHD1 or DCAF1 are observed in the crystal structure [51].
1508 H.I. Ciftci et al. / FEBS Letters 589 (2015) 1505–1514One plausible explanation for the ability of high levels of WT
Vpx to prevent SAMHD1 degradation, while the P106A and
P109A do not, is that Vpx multimerization at high concentration
interferes with formation of the Cul4-DDB1-DCAF1 E3 ligase com-
plex, since in this complex Vpx exists as a monomer [51]. To eval-
uate Vpx oligomerization, we next examined the protein–protein
interactions of Vpx and its mutants by immunoprecipitation of
FLAG- and HA-tagged Vpx expressed in transfected cells with an
anti-FLAG antibody. The immunoprecipitated complex wasimmunoblotted using an anti-HA antibody. As shown in Fig. 3(e),
the P109A mutant was clearly deﬁcient in Vpx–Vpx interactions
compared with those observed for the WT and the other mutants
of Vpx, while the other mutants P4L and P103A have moderate
deﬁciency (By quantitative analysis of bands, pull-downed P109A
mutant is estimated to be reduced to 10% compared to WT. In
P4L and P103A, pull-downed proteins are the about the
half of WT.) The same result was observed using another




H.I. Ciftci et al. / FEBS Letters 589 (2015) 1505–1514 1509Kusabira–Green system [47]. As shown in Fig. 3(f), in cells
co-transfected with expression vectors for Vpx fused with
Kusabira–Green-N- and C-terminal fragments, larger numbers of
cells with ﬂuorescence are seen, compared with cells expressed
with P109A mutant, showing the weaker Vpx–Xpx interaction in
P109A mutant. We next examined whether this character
is seen in the other mutants of PPM. As shown in Fig. 3(g), the
P106A mutant has character similar to P109A. The results are
consistent with the previous report [52] that PPM containing P106
and P109 is critical for Vpx–Vpx interactions. These support our
hypothesis that SAMHD1 degradation and Vpx multimerization
are related.3.4. The defective replication stages of HIV-2 carrying C87A or P109A
mutant Vpx
We next investigated defects in the replication of HIV-2 carry-
ing C87A or P109A mutant Vpx. Ideally, Vpx protein expressed
from the HIV-2 genome should be detected using an anti-Vpx anti-
body. Evaluation of the sensitivity of the antibody for the detection
of FLAG-tagged Vpx or it mutants (C87A or P109A) showed that the
HIV-2 Vpx monoclonal antibody 6D2.6 reacted with C87A
(Fig. 4(a)), but not with P109A, although expression of the mutant
Vpx was conﬁrmed using anti-FLAG antibody. We then transfected






Fig. 3. Degradation of SAMHD1 in the presence of various amounts of Vpx mutant C87A or P109A. (a) The same analysis as Fig. 2(a) using pEF-FxC87A or pEF-FxP109A instead
of pEF-Fvpx [37]. Blots were developed as long as possible to increase the sensitivity of Vpx detection. (b) Immunoblot analysis of proteins in 293T cells co-transfected with
pcDNA hSAMHD1 (1.4 lg), and pEF-Fvpx or its mutants (1.9 lg). Mock, pcDNA3.1(-) + pEF1/myc-HisA; -, pcDNA hSAMHD1 + pEF1/myc-HisA. (c) The same analysis as Fig. 2(b)
using PPM mutants of pEF-Fvpx. (d) The same analysis as (b) using PPM mutants of pEF-Fvpx. (e) Immunoblot analysis of proteins immunoprecipitated with or without anti-
FLAG antibody from lysates of 293T cells co-transfected with pEF-Fvpx or its mutants (5.0 lg), and pEF-HVpx or its mutants (5.0 lg). Cells were lysed with TNE buffer, and the
lysate was immunoprecipitated with anti-FLAG M2 afﬁnity gel. The gel was washed with TNE buffer (8 times). Immunoblotting of the immunoprecipitated complex was
performed. (f) Bimolecular ﬂuorescence complementation assay using Kusabira–Green system. To normalize the amounts of conjugated proteins between Vpx and its P109A
mutant, amount of phmKGN-Vpx and phmKGC-Vpx was reduced, and a V-ATPase inhibitor was used. Vectors phmKGN-Vpx and phmKGC-Vpx (0.0786 lg each), or phmKGN-
xP109A and phmKGC-xP109A (0.393 lg each) were co-transfected into 293T cells, and incubated in the presence of Baﬁlomycin A1 (0.1 lM). The cells were observed using
ﬂuorescence microscope 18 h post transfection. After observation, cells were lysed, and immunoblot analysis was performed. (g) The same analysis as (e) using PPM mutants,
other than P103A and P104A, of pEF-Fvpx and pEF-Hvpx.




H.I. Ciftci et al. / FEBS Letters 589 (2015) 1505–1514 1511P109A). Intercellular expression levels and virion-packaged protein
levels were analyzed by western blotting. As shown in Fig. 4(b), the
C87Amutant of Vpx was not observed in either the cells or the viri-
ons. In contrast, incorporation of the P109A mutant in virions was
conﬁrmed by detection using the HIV-2 Rod polyclonal antibody.
The eitope of this antibody would contain P109, unlike HIV-2 Vpx
monoclonal antibody 6D2.6. However, detection of Vpx in the cells
was not possible because of the low sensitivity of the antibody.
We next analyzed effects of the P109A mutation on early and
late replication phases of HIV-2. Since transfection into macro-
phages is difﬁcult, we used PMA-differentiated THP-1 cells as
macrophages-like cells. Reduced infectivity of the P109A mutant
in these cells has been reported previously [53]. VSV-G pseudo-
typed virus was prepared from 293T cells according to our previ-
ous method [10], and equal amounts of virus was infected into
macrophage-like cells. DNA was extracted, and analyzed using
quantitative PCR. As shown in Fig. 4(c), the Vpx-minus virus was
defective at the reverse transcription stage, as previously reported.
The P109A mutant showed the same defect, but to a lesser degree
of severity compared with DVpx. In both viruses, the amount of
2-LTR DNA, which is a marker of nuclear translocation ability,
was slightly lower than reverse transcription product; this may
be caused by the defect in reverse transcription. Subsequently,
the macrophage-like cells were transfected with the env-minus
HIV-2 infectious clone and its P109A counterpart. Equal amounts
of P109A and WT viruses were produced, showing no defect in
the late replication phase (Fig. 4(d)).
Next, the levels of endogenous SAMHD1 in the macrophage-like
cells and monocyte-derived macrophages infected with pseudo
virus carrying P109A mutant Vpx, was conﬁrmed by immunoblot
analysis. Degradation of endogenous SAMHD1 was observed in
cells infected with the WT virus, but not in those infected with
the DVpx virus (Fig. 4(e)). Surprisingly, SAMHD1 was degraded
in cells infected with the virus carrying the P109A mutant Vpx,
although the degradation was less effective than that observed in
the cells infected with the virus carrying the WT Vpx. In contrast,
when the same titer of pseudo virus was used to infect 293T cells,
P109A mutant degraded endogenous SAMHD1 with the same efﬁ-
ciency as the WT. These results suggested that P109 has a role in
facilitating the degradation of SAMHD1 speciﬁcally in macro-
phages, allowing efﬁcient reverse transcription. We ﬁnally exam-
ined that the role to facilitate the SAMHD1 degradation is carried
by the other mutants of PPM. As shown in Fig. 4(f), PPM mutantsexcept P103A degrade SAMHD1 less effectively or does not
degrade at all in macrophage-like cells, suggesting each amino acid
from P104 to P108 has the role similar to P109.
4. Discussion
We ﬁrst examined the expression proﬁles of FLAG-tagged Vpx
mutants from expression vectors. Next, using these Vpx mutants,
their ability to degrade SAMHD1 in 293T cells was examined.
The observation that excess amount of Vpx prevents the degrada-
tion of SAMHD1 is consistent with previous results [54] of a study
investigating the turnover of UNG2 by HIV-1 Vpr, a similar protein
to Vpx. We suggest that the amount of Vpx protein should be care-
fully determined to allow useful interpretation of experimental
results. In comparisons of the ability of mutants showing sufﬁcient
protein expression to degrade SAMHD1 with their ability to confer
viral infectivity in MDMs, relatively good correlation was observed.
Among the mutants that did not show a good correlation, we
focused on C87A and P109A, and examined their properties in
detail. We found that expression level of C87A mutant was extre-
mely low when HIV-2 infectious clone was used for expression.
The reason for the difference in the expression level from the full
genomic infectious clone and the FLAG-tagged Vpx expression vec-
tor remains to be elucidated. The recently resolved crystal struc-
ture of Vpx [51] shows that C87 is one of the four amino acids
coordinating a zinc ion, which is likely important for proper folding
and protein stability.
Our analysis in detail of the P109A mutant revealed that P109
has two roles in regulating the degradation of SAMHD1: to facili-
tate Vpx–Vpx interactions, preventing SAMHD1 degradation in
the presence of high levels of Vpx, and to facilitate degradation
of SAMHD1 in macrophages speciﬁcally. The P109 residue of Vpx
is located in the C-terminal PPM, which uniquely carrying seven
consecutive prolines starting from P103. Using mutants in which
three prolines in the C-terminal part of the PPM were substituted
by alanine residues, we showed that this motif in HIV-2 Vpx is crit-
ical for its efﬁcient expression [37]. This could be a reason why
there are at least ﬁve prolines in the PPM (deletion of three proli-
nes results in dysfunction, showing four are not enough for expres-
sion of Vpx); however, this does not explain the necessity for seven
prolines. This study shows the requirement of seven prolines to
facilitate degradation of SAMHD1 in macrophages. It has been








Fig. 4. Analysis of defective stages of replication of HIV-2 carrying Vpx C87A or P109A mutant. (a) Immunoblot analysis with HIV-2 Vpx monoclonal antibody 6D2.6 (anti-
Vpx, mono) of proteins in 293T cells transfected with pEF-Fvpx [37] or its C87A or P109A mutant (3.3 lg). (b) Immunoblot analysis with anti-Vpx antibody [HIV-2 Vpx
monoclonal antibody 6D2.6 (anti-Vpx, mono) or HIV-2 Rod polyclonal antibody (anti-Vpx, poly)] of proteins in 293T cells transfected with pGL-AN [38] or its mutant (C87A or
P109A) [10], and virions produced by the cells. Left panel: pGL-AN or its C87A mutant (0.5 lg) was transfected. Virions were concentrated by Viro-Adembeads. Right panel:
pGL-AN or its P109Amutant (20 lg) was transfected. Virions were prepared by ultracentrifugation using sucrose as previously described [48]. p27 was determined by SIV p27
antigen ELISA kit. Mock, pUC19; DVpx, pGL-St [38]. (c) Quantitative estimation of viral DNA synthesis in PMA-differentiated THP-1 cells infected with virus produced from
293T cells which were co-transfected with env-minus pGL-Ns [9] or its P109A mutant (5 lg), and pCMV-G [59] (5 lg). THP-1 cells were differentiated by stimulation with
phorbol-12-myristate-13-acetate (PMA) at 300 nM and incubation for 3 days. Cells were infected with VSV-G pseudo virus (normalized by 250 ng of p27) using DNase I,
MgCl2, EGTA and DEAE-dextran as previously described [10], and incubated for 1 d. DNA was extracted from and analyzed by quantitative PCR. As a control, supernatant of
293T cells transfected with env-minus pGL-Ns (5 lg) and pUC (5 lg) was used instead of virus, and analyzed. The control amount of DNA was subtracted from the each DNA
amount, and the resultant value was shown. DVpx, pGL-Ns/St [9]+pCMV-G. (d) Amount of virus released from PMA-differentiated THP-1 cells transfected with pGL-Ns or its
P109A mutant. The cells were transfected by Lipofectamine 3000 with b-actb-gal (kindly provided by Dr. Shunsuke Ishii, Riken Tsukuba Institute) (0.1 lg) and pGL-Ns or its
mutants (0.4 lg). The cells were incubated for 4 days before the amount of virus was examined using a SIV p27 antigen ELISA kit. Cells were ﬁxed with 0.2% glutaraldehyde
solution, and incubated with X-gal solution (1 mg/ml) for 16 h, and number of blue stained cells was counted to normalize transfection efﬁciency. DVpx, pGL-Ns/St. (e)
Immunoblot analysis of proteins in PMA-differentiated THP-1, 293T cells, and monocyte-derived macrophages infected with virus used in (c). The cells were infected with the
pseudo virus (250 ng of p27 amount/0.88  105 cells) using only DEAE-dextran, and incubated for 1 d. Cell lysates were analyzed by western blotting. Mock, pUC19; DVpx,
pGL-Ns/St + pCMV-G. (f) The same analysis as (e) using PPM mutants of pGL-Ns [9] and PMA-differentiated THP-1.
1512 H.I. Ciftci et al. / FEBS Letters 589 (2015) 1505–1514SAMHD1 [52,55]; however, this study shows for the ﬁrst time that
this phenomenon of dispensability is not observed in macrophages
or macrophage-like cells.
This and previous [37,56] studies suggest that the PPM of Vpx
has multiple functions, facilitating translation of Vpx and degrada-
tion of SAMHD1 in macrophages. PPM also has ability to oligomer-
ize Vpx, regulating SAMHD1 degradation negatively in the presence
of high levels of Vpx. In this way, the amount of Vpx incorporated
into virions may be adjusted to be appropriate for the degradation.
We are now in the process of elucidating the molecular mechanism
responsible for the functions of the PPM in Vpx protein.Acknowledgments
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